Role of genetic and molecular profiling in sarcomas (Q38458016)

3 September 2017

1 reference

title

Role of genetic and molecular profiling in sarcomas (English)

1 reference

3 September 2017

Scott M Norberg

1 reference

3 September 2017

Sujana Movva

series ordinal

1 reference

3 September 2017

publication date

1 May 2015

1 reference

Current Treatment Options in Oncology

3 September 2017

published in

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

The role of genetic testing in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Soft tissue sarcomas with complex genomic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gene expression profiling of human sarcomas: insights into sarcoma biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gene expression signatures of primary and metastatic uterine leiomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

A gene expression signature associated with metastatic outcome in human leiomyosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Prediction of high risk Ewing's sarcoma by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

SYT–SSXGene Fusion as a Determinant of Morphology and Prognosis in Synovial Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Kif18A is involved in human breast carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Kinesin 18A expression: clinical relevance to colorectal cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Histology-Driven Chemotherapy in Soft Tissue Sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Activity of Sorafenib against desmoid tumor/deep fibromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Clinical management of uterine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Low-grade endometrial stromal sarcoma: hormonal aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Epithelioid hemangioendothelioma of the kidney treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

That's the "GIST" of it: use of adjuvant imatinib after resection of a primary GI stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Kinase domain mutations in cancer: implications for small molecule drug design strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Targeted therapy in GIST: in silico modeling for prediction of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

GIST treatment options after tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Consistent MYC and FLT4 gene amplification in radiation‐induced angiosarcoma but not in other radiation‐associated atypical vascular lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Induction of sarcomas by mutant IDH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Molecular characterisation of soft tissue tumours: a gene expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-015-0339-3

Desmoid tumours treated with triphenylethylenes

21 January 2018

1 reference

12 December 2020

Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics

1 reference

12 December 2020

Soft tissue sarcomas of adults: state of the translational science.

1 reference

12 December 2020

Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas

1 reference

12 December 2020

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

12 December 2020

Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients

1 reference

12 December 2020

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

1 reference

12 December 2020

Recurrent PTPRB and PLCG1 mutations in angiosarcoma

1 reference

12 December 2020

Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.

1 reference

12 December 2020

Synovial sarcoma of children and adolescents: The prognostic role of axial sites

1 reference

12 December 2020

Safety of denosumab in giant-cell tumour of bone

1 reference

12 December 2020

The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma

1 reference

12 December 2020

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

1 reference

12 December 2020

Molecular diagnostics of soft tissue tumors

1 reference

12 December 2020

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

1 reference

12 December 2020

Differential gene expression in leiomyosarcoma

1 reference

12 December 2020

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

1 reference

12 December 2020

Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions

1 reference

12 December 2020

Synovial sarcoma. Uniform response of metastases to high dose ifosfamide

1 reference

12 December 2020

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

12 December 2020

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

1 reference

12 December 2020

Contribution of cytogenetics to the management of poorly differentiated sarcomas

1 reference

12 December 2020

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

12 December 2020

Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics

1 reference

12 December 2020

10.1007/S11864-015-0339-3

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1035951837

0 references

1 reference